Clinical Research Site
Excel is fully capable of conducting sponsored clinical research trials in the field of radio-pharmaceuticals and nuclear medicine procedures. All our research staff are GCP Trained and CITI certified consisting of highly trained, board-certified investigators, study coordinators, patient recruiters and support staff. At Excel, you will find areas designed to safely handle and administer radiopharmaceuticals, patient care areas, and physician interpretation resources.
The Excel Clinical Research Department (ECRD) is a dedicated department to assist investigators in their clinical trials. Our team is fully trained regarding rules and regulations of conducting human research, FDA requirements, and IRB compliance. We offer our expertise in conducting clinical research to a variety of academic institutions and pharmaceutical companies. Working closely with CRO’s & IRB, the ECRD team can conduct your sponsored clinical trials in the field of oncology radiopharmaceuticals.
At Excel Nuclear Oncology Center, Your clinical trials will be reviewed promptly, and budget will be provided in less than 2 weeks, in most cases. Excel is fully capable of conducting sponsored clinical research trials in the field of radiopharmacuticals and nuclear medicine procedures. All our research staff are GCP Trained and CITI certified consisting of highly trained, board certified investigators, study coordinators, patient recruiters and support staff. At Excel, you will find areas designed to safely handle and administer radiopharmaceuticals, patient care areas, and physician interpretation resources.
Excel with its broad oncology network can expedite Subject recruitment for your clinical trials. Our ECRD team has high experience and track record in clinical research Project coordination, Technologist training, and Management of data and report forms. Our regulatory department is in full compliance with FDA, GCP, ICH and IRB guidelines. Our highly trained and efficient staff deliver exceptional levels of service completed with the utmost professionalism and provide sponsors with reliable, quality data.
Therapy
AlphaMedix trial -NCT03466216
AlphaMedix™ (²¹²Pb-DOTAMTATE) is a radiotherapeutic drug indicated in subjects with unresectable, metastatic somatostatin receptor (SSTR) positive neuroendocrine tumors (NETs).
Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225, being an alpha emitter, is expected to have higher efficacy and fewer side effects compared to the beta-emitters such as Lutetium-177. We have performed a meta-analysis to assess the therapeutic responses, survival effects, and significant side effects of Ac-225 PSMA RLT in patients with mCRPC.
Diagnostics
Copper Cu 64 PSMA I&T PET Imaging: This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Call Now for Info on Active Clinical Trials
Susan Cork
Therapy Coordinator
Main Line: 713-781-6200 x3203
Direct Line: 713.341.3203
Fax: 713-781-6206